Form 4: Avidity CCO Sells Shares Under Pre-Arranged Plan

Avidity Biosciences' Chief Commercial Officer, Eric Mosbrooker, sold 6,563 shares of common stock for approximately $47.07 per share after exercising options.

Summary

• Eric Mosbrooker, Chief Commercial Officer of Avidity Biosciences, Inc., executed a pre-planned transaction on September 3, 2025.
• Mosbrooker exercised options to acquire 6,563 shares of common stock at an exercise price of $9.05 per share.
• Concurrently, he sold 6,563 shares of common stock at a weighted-average price of $47.0723 per share, with individual sales ranging from $46.13 to $47.66.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on September 11, 2024.
• Following these transactions, Mosbrooker directly owns 55,000 shares of common stock and 183,750 stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can be seen negatively, the pre-planned nature via a 10b5-1 plan mitigates concerns about immediate negative news. The significant profit from the option exercise is positive for the insider.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to immediate negative information.
• The sale price of $47.0723 per share is significantly higher than the exercise price of $9.05, indicating a substantial gain for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing for a biotechnology company. Such filings are common across all industries for executives managing their equity compensation.

Related Party Transactions

• The reported transactions involve an officer of Avidity Biosciences, Inc. (Eric Mosbrooker) exercising stock options and selling shares, which is a common form of related party transaction for executive compensation.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The reduction in direct insider ownership is minor relative to total outstanding shares.
• Management: The Chief Commercial Officer realized a significant gain from his equity compensation.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned insider transaction by the Chief Commercial Officer. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. The transaction was executed under a Rule 10b5-1 plan, suggesting it was a planned liquidity event rather than a reaction to new material information. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a basis for a 'buy' or 'sell' decision.

Keywords

Avidity Biosciences, RNA, Eric Mosbrooker, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Chief Commercial Officer